Last reviewed · How we verify
SHR8554 Injection
SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist.
SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | SHR8554 Injection |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants (PHASE1)
- A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery (PHASE2, PHASE3)
- A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery. (PHASE2)
- A Clinical Study of SHR8554 Injection for the Treatment of Pain After Abdominal Surgery. (PHASE3)
- A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |